Registry for Systemic Eczema Treatments

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The Registry for Systemic Eczema Therapies (RESET) registry is a database and biospecimen repository for patients with pediatric-onset atopic dermatitis (AD) who have used or will initiate any systemic treatment(s) for AD. The goal of the registry is to enable more efficient research recruitment and data collection as well as timely notification to enrollees about newly FDA-approved treatments for AD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 26
Healthy Volunteers: f
View:

• Age \<26 years old

• Current physician diagnosis of atopic dermatitis

• Provide signed informed consent if ≥ 18 years old

• Provide signed informed consent by parent or legal guardian (if \<18 years old) and informed assent if applicable

• Subject and/or parent/legal guardian is willing to be contacted in the future by study staff

• Seen for clinical care at Johns Hopkins since 1/1/2017

• Previously on, currently on, or planning to initiate (within next 6 months) a systemic AD therapy

Locations
United States
Maryland
Johns Hopkins University
RECRUITING
Baltimore
Contact Information
Primary
Rebecca Urbonas, BS
rurbona1@jh.edu
813-300-1317
Backup
Sumrah Jilani
sjilani3@jhmi.edu
Time Frame
Start Date: 2024-01-17
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 400
Treatments
Methotrexate
Participants who have received methotrexate for atopic dermatitis.
Cyclosporine
Participants who have received cyclosporine for atopic dermatitis.
Mycophenolate mofetil
Participants who have received mycophenolate mofetil for atopic dermatitis.
Azathioprine
Participants who have received azathioprine for atopic dermatitis.
Dupilumab
Participants who have received dupilumab for atopic dermatitis.
Tralokinumab
Participants who have received tralokinumab for atopic dermatitis.
Upadacitinib
Participants who have received upadacitinib for atopic dermatitis.
Abrocitinib
Participants who have received abrocitinib for atopic dermatitis.
Related Therapeutic Areas
Sponsors
Collaborators: Doris Duke Charitable Foundation
Leads: Johns Hopkins University

This content was sourced from clinicaltrials.gov